Matthew Scott Harris Altimmune, Inc. (ALT) insider trading activity

Matthew Scott Harris is Chief Medical Officer of Altimmune, Inc.. Currently has a direct ownership of 53,633 shares of ALT, which is worth approximately $352,905. The most recent transaction as insider was on Feb 02, 2024, when has been sold 2,332 shares (Common Stock, par value $0.0001) at a price of $9.32 per share, resulting in proceeds of $21,734. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 53.6K

0% 3M change

61.01% 12M change

Total Value Held $352,905

Matthew Scott Harris Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 02 2024	SELL Payment of exercise price or tax liability	$21,734 $9.32 p/Share	2,332 Reduced 4.17%	53,633 Common Stock, par valu...
Feb 02 2024	BUY Exercise of conversion of derivative security	-	7,775 Added 12.2%	55,965 Common Stock, par valu...
Feb 01 2024	SELL Payment of exercise price or tax liability	$17,793 $9.88 p/Share	1,801 Reduced 3.6%	48,190 Common Stock, par valu...
Feb 01 2024	BUY Exercise of conversion of derivative security	-	6,166 Added 10.98%	49,991 Common Stock, par valu...
Jan 31 2024	BUY Grant, award, or other acquisition	$8,761 $2.69 p/Share	3,257 Added 6.92%	43,825 Common Stock, par valu...
Jan 30 2024	SELL Payment of exercise price or tax liability	$26,548 $9.8 p/Share	2,709 Reduced 6.26%	40,568 Common Stock, par valu...
Jan 30 2024	BUY Exercise of conversion of derivative security	-	9,275 Added 17.65%	43,277 Common Stock, par valu...

Jul 31 2023	BUY Grant, award, or other acquisition	$1,941 $2.81 p/Share	691 Added 1.99%	34,002 Common Stock, par valu...
Mar 23 2023	BUY Open market or private purchase	$42,200 $4.22 p/Share	10,000 Added 23.09%	33,311 Common Stock, par valu...
Feb 02 2023	SELL Payment of exercise price or tax liability	$35,554 $15.04 p/Share	2,364 Reduced 9.21%	23,311 Common Stock, par valu...
Feb 02 2023	BUY Exercise of conversion of derivative security	-	7,775 Added 23.24%	25,675 Common Stock, par valu...
Feb 01 2023	SELL Payment of exercise price or tax liability	$30,081 $13.78 p/Share	2,183 Reduced 10.87%	17,900 Common Stock, par valu...
Feb 01 2023	BUY Exercise of conversion of derivative security	-	6,166 Added 23.49%	20,083 Common Stock, par valu...
Jan 31 2023	BUY Grant, award, or other acquisition	$13,232 $10.21 p/Share	1,296 Added 8.52%	13,917 Common Stock, par valu...
Jul 31 2022	BUY Grant, award, or other acquisition	$7,381 $6.86 p/Share	1,076 Added 7.86%	12,621 Common Stock, par valu...
Feb 28 2022	SELL Open market or private sale	$225,600 $7.52 p/Share	30,000 Reduced 72.21%	11,545 Common Stock, par valu...
Feb 28 2022	BUY Exercise of conversion of derivative security	$57,600 $1.92 p/Share	30,000 Added 41.93%	41,545 Common Stock, par valu...
Feb 01 2022	SELL Payment of exercise price or tax liability	$17,420 $7.98 p/Share	2,183 Reduced 15.9%	11,545 Common Stock, par valu...
Feb 01 2022	BUY Exercise of conversion of derivative security	-	6,166 Added 30.99%	13,728 Common Stock, par valu...
Jan 31 2022	BUY Grant, award, or other acquisition	$12,348 $6.86 p/Share	1,800 Added 19.23%	7,562 Common Stock, par valu...
Jul 31 2021	BUY Grant, award, or other acquisition	$5,590 $7.71 p/Share	725 Added 11.18%	5,762 Common Stock, par valu...
Jan 31 2021	BUY Grant, award, or other acquisition	$11,752 $12.14 p/Share	968 Added 16.12%	5,037 Common Stock, par valu...
Nov 12 2020	SELL Open market or private sale	$40,230 $10.02 p/Share	4,015 Reduced 49.67%	4,069 Common Stock, par valu...

MSH

Matthew Scott Harris

Chief Medical Officer

Gaithersburg, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALT shares.

Notify only if

Value

Insider Trading

Get notified when an Altimmune, Inc. insider buys or sells ALT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Altimmune, Inc.

Track Activities on ALT

Account